Kite Pharma (KITE) Reports Q1 Loss Per Share of 60c

Kite Pharma (NASDAQ: KITE) reported Q1 EPS of ($0.60), $0.48 better than the analyst estimate of ($1.08). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $4.61 million.

"Our ZUMA-1 update at AACR last month highlighted the potential of KTE-C19, our breakthrough immunotherapy candidate, to put patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL), a patient population burdened with a short life expectancy and limited treatment options, into a durable complete remission," noted Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer. “We remain on track to provide interim data from the pivotal phase 2 portion of ZUMA-1 later this year and plan to submit the KTE-C19 registration filing to the U.S. Food and Drug Administration (FDA) by the end of 2016.”

“Our commitment to delivering a breakthrough personalized cell therapy to cancer patients now extends fully to our manufacturing and market planning areas. Validation and qualification activities at our state-of-the-art commercial manufacturing facility are underway. The commercial team is actively evaluating a broad range of market and payor strategies for making KTE-C19 available to patients with a significant unmet need.”

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c